Phase II Study Combines NC410, FOLFIRINOX, and Immune Modulators in Metastatic PDAC

The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins is investigating the safety profile and potential novel toxicities of NC410 combined with FOLFIRINOX and checkpoint inhibitors (nivolumab with or without ipilimumab) in treatment-naïve metastatic pancreatic ductal adenocarcinoma. This study aims to optimize combination regimens for enhanced efficacy in a challenging patient population.